| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11684632 | TAKEDA PHARMS USA | Maribavir isomers, compositions, methods of making and methods of using |
Jan, 2032
(7 years from now) | |
Livtencity is owned by Takeda Pharms Usa.
Livtencity contains Maribavir.
Livtencity has a total of 1 drug patent out of which 0 drug patents have expired.
Livtencity was authorised for market use on 23 November, 2021.
Livtencity is available in tablet;oral dosage forms.
Livtencity can be used as treatment of patients with post-transplant cytomegalovirus (cmv) infection/disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet, where the patient is a stem cell, kidney, or liver transplant recipient.
Drug patent challenges can be filed against Livtencity from 23 November, 2025.
The generics of Livtencity are possible to be released after 04 January, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2026 |
| Orphan Drug Exclusivity(ODE-388) | Nov 23, 2028 |
Drugs and Companies using MARIBAVIR ingredient
NCE-1 date: 23 November, 2025
Market Authorisation Date: 23 November, 2021
Treatment: Treatment of patients with post-transplant cytomegalovirus (cmv) infection/disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet, where the patient is a stem cell, ...
Dosage: TABLET;ORAL
LIVTENCITY family patents
